The three G-protein-coupled cannabinoid receptor subtypes currently recognized are central (CB1), peripheral (CB2), and GPR55. The majority of CB1 receptors are found at central and peripheral nerve terminals. CB2 receptors are mainly found in immune cells and non-neuronal tissues where they regulate cytokine release and cell migration. According to recent reports, the CNS may also express CB2 receptors. Non-CB1/CB2 receptors known as GPR55 show affinity for endogenous, botanical, and synthetic cannabinoids. Anandamide and 2-arachidonylglycerol are examples of endogenous ligands for cannabinoid receptors.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V1521 | Org 27569 | 868273-06-7 | Org 27569 (Org27569; Org-27569), similar to theanorectic antiobesity drug rimonabant, is a novel, potent and selective allosteric modulator of cannabinoid CB1 receptor with anti-obesity effects. |
|
V26985 | Otenabant (CP-945598) | 686344-29-6 | Otenabant free base (also known as CP-945,598) is a novel, potent and highly selective cannabinoid receptor CB1 antagonist with Ki of 0.7 nM, it exhibits >10,000-fold greater selectivity against human CB2 receptor. |
|
V1518 | Otenabant (CP-945598) HCl | 686347-12-6 | Otenabant HCl (also known as CP-945,598; CP 945,598; CP-945598), the hydrochloride salt of Otenabant, is a novel, potent and highly selective cannabinoid receptor CB1 antagonist with potential anti-obesity effect. |
|
V71577 | Palmitoyl serinol-d5 (N-Palmitoyl serinol-d5) | 946524-35-2 | Palmitoyl serinol-d5 is the deuterated form of Palmitoyl serinol. |
|
V81086 | Pergolide-d7 mesylate (Pergolide methanesulfonate-d7; LY127809-d7) | Pergolide-d7 (mesylate) is the deuterium labelled form of Pergolide mesylate. | |
|
V71575 | Pirnabine | 19825-63-9 | Pirnabine is a cannabinoid receptor ligand. |
|
V71604 | PM226 | 1949726-13-9 | PM226 is a selective cannabinoid CB2R agonist (Ki (CB2R)=13 nM; EC50 (CB2R)=39 nM; Ki (CB1R) >40 μM) with neuro-protection properties in vitro and in vivo. |
|
V80472 | Pramipexole-d7 dihydrochloride (pramipexole d7 dihydrochloride) | Pramipexole-d7 (di-HCl) is the deuterium labelled form of Pramipexole di-HCl. | |
|
V71581 | R-2 Methanandamide | 157182-47-3 | R-2 Methanandamide (Compound 2) is a cannabinoid Anandamide analog with a Ki of 119 nM for cannabinoid receptors (Ki determined by PMSF and rat meninges). |
|
V1515 | Rimonabant (SR141716) | 168273-06-1 | Rimonabant (formerly known as SR-141716; A-281; A281; SR 141716A; Acomplia; Zimulti), an anorectic antiobesity drug once used in EU but withdrawn from marketdue to serious psychiatric side effects, is a novel, potent and selective antagonist (inverse agonist) of cannabinoid CB1 receptor. |
|
V3565 | Rimonabant HCl (SR141716) | 158681-13-1 | Rimonabant (also known as SR141716, SR-141716A; A 281) is a novel, potent and selective antagonist (inverse agonist) of cannabinoid CB1 receptor with IC50 of 13.6 nM and EC50 of 17.3 nM in hCB1 transfected HEK 293 membrane. |
|
V2596 | RTICBM-189 | 551909-15-0 | RTICBM-189 (RTICBM189) is brain penetrant and allosteric modulator of the cannabinoid 1 (CB1) receptor (pIC50 = 7.54 in Ca2+ mobilization assay). |
|
V71595 | RVD-Hpα | 1193362-76-3 | RVD-Hpα is an alpha-hemoglobin-derived peptide containing three additional amino acid (AA)s and is a CB1 cannabinoid receptor agonist. |
|
V71588 | RVD-Hpα TFA | 1431329-51-9 | RVD-Hpα TFA is the N-terminally extended form of human hemopressin that works as a selective CB1 receptor agonist. |
|
V71570 | S-1 Methanandamide ((S)-Methanandamide) | 157182-50-8 | S-1 Methanandamide ((S)-Methanandamide) is an Anandamide analogue and a CB1 receptor ligand with a Ki of 173 nM. |
|
V71578 | S-2 Methanandamide | 157182-48-4 | S-2 Methanandamide is a potent cannabinoid receptor 1 agonist/activator with IC50s of 173 nM (with PMSF) and 8216 nM for CB1 and CB2, respectively. |
|
V71560 | S-777469 | 885496-53-7 | S-777469 is a selective, orally bioactive cannabinoid type 2 receptor (CB2) agonist/activator with a Ki of 36 nM. |
|
V15224 | SR144528 | 192703-06-3 | SR144528 (SR-144528; SR 144528) is a novel and potent cannabinoid (CB2) receptor or antagonist or inverse agonist with Ki of 0.6 nM and 400 nM against CB2 and CB1 receptors, respectively. |
|
V71552 | Synaptamide (Dehydroepiandrosteron(DHEA); Docosahexaenoyl ethanolamide) | 162758-94-3 | Synaptamide (Dehydroepiandrosteron; DHEA) is an endogenously produced metabolite and a structural analog of Anandamide. |
|
V71567 | Synaptamide-d4 (Dehydroepiandrosteron(DHEA)-d4; Docosahexaenoyl ethanolamide-d4) | 946524-43-2 | Synaptamide-d4 is the deuterated form of Synaptamide. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
